Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
NCT02521051 · Massachusetts General Hospital · PHASE1/PHASE2 · terminated · last registry update 2025-05-13 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | Open Targets' class: insufficient enrollment | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-30Results posted on the registry: Xcovery Holdings, Inc., Phase I: X-396 (ensartinib) + Phase II: X-396 (ensartinib) (NCT01625234)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2025-06-11Results posted on the registry: Pfizer, Lorlatinib (NCT04362072)
- 2025-05-02Phase 3 first posted: The First Affiliated Hospital of Guangzhou Medical University, Icotinib + Rezivertinib (NCT06955325)
- 2025-04-24Also stopped (withdrawn): M.D. Anderson Cancer Center, Brigatinib + Carboplatin (NCT06522360)
- 2025-03-26Results posted on the registry: ETOP IBCSG Partners Foundation, Alectinib (NCT03445000)
- 2025-03-05Phase 3 first posted: Guangdong Association of Clinical Trials, lorlatinib (NCT06858410)
- 2025-02-19Results posted on the registry: Takeda, Brigatinib + Alectinib (NCT03596866)
- 2025-01-09Phase 3 first posted: Nuvalent Inc., Neladalkib (NVL-655) + Alectinib (NCT06765109)
- 2024-12-20Results posted on the registry: Pfizer, Lorlatinib (NCT04541706)
- 2024-11-08Results posted on the registry: Pfizer, Crizotinib (NCT03672643)
- 2024-11-08Also stopped (terminated): Pfizer, Crizotinib (NCT03672643)
- 2024-10-08Also stopped (withdrawn): ETOP IBCSG Partners Foundation, Brigatinib + Durvalumab (NCT05718297)
- 2024-10-02Phase 3 first posted: Hoffmann-La Roche, Alectinib + Cisplatin (NCT06624059)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-08-26Phase 3 first posted: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a drug against ALK (NCT06569420)
- 2024-08-21Phase 3 first posted: Nuvation Bio Inc., Taletrectinib + Crizotinib (NCT06564324)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision